Biweekly CHOP biweekly THP-COP regimen in the treatment of aggressive non-Hodgkin's lymphoma - Comparison of doxorubicin and pirarubicin: A randomized phase II study.

被引：0

作者：

Tsurumi, H

Sawada, M

Yamada, T

Hara, T

Goto, H

Fukuno, K

Shimizu, M

Yoshikawa, T

Kanemura, N

Takahashi, T

Oyama, M

Ozawa, K

Moriwaki, H

机构：

[1] Gifu Univ, Sch Med, Dept Internal Med 1, Gifu 500, Japan

[2] Kisogawa Hosp, Dept Internal Med, Kisogawa, Aichi, Japan

[3] Takayama Red Cross Hosp, Dept Internal Med, Takayama, Gifu, Japan

[4] Gifu Municipal Hosp, Dept Hematol, Gifu, Japan

[5] Jichi Med Sch, Dept Hematol, Minami Kawachi, Tochigi 32904, Japan

来源：

BLOOD | 2001年 / 98卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1460

引用

页码：346A / 346A

页数：1

共 50 条

[21] Influence of amifostine on toxicity of CHOP in elderly patients with aggressive non-Hodgkin's lymphoma -: a phase II study
Späth-Schwalbe, E
Lange, C
Genvresse, I
Krüuger, L
Eucker, J
Schweigert, M
Sezer, O
Budach, V
Possinger, K
[J]. ANTI-CANCER DRUGS, 2002, 13 (04) : 395 - 403
[22] Prospective randomized study comparing MEMID with a chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma
Chamorey, E
Gressin, R
Peyrade, F
Rossi, JF
Lepeu, G
Foussard, C
Harrousseau, JL
Fabbro, M
Richard, B
Delwail, V
Maisonneuve, H
Vilque, JP
Thyss, A
[J]. ONCOLOGY, 2005, 69 (01) : 19 - 26
[23] A randomized control clinical study: DNCE regimen for treatment of advanced aggressive non-Hodgkin lymphoma
Liu, X.
Wang, H.
[J]. ANNALS OF ONCOLOGY, 2008, 19 : 219 - 219
[24] Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma
Vose, JM
Link, BK
Grossbard, ML
Czuczman, M
Grillo-Lopez, A
Gilman, P
Lowe, A
Kunkel, LA
Fisher, RI
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (02) : 389 - 397
[25] Randomized comparison of mobilization kinetics of circulating CD34+cells between biweekly CHOP and dose-escalated CHOP with the prophylactic use of lenograstim (glycosylated rHuG-CSF) in aggressive non-Hodgkin's lymphoma
Itoh, K
Ohtsu, T
Sasaki, Y
Ogura, M
Morishima, Y
Kasai, M
Chou, T
Yoshida, K
Ohno, T
Mizorogi, F
Uike, N
Sai, T
Taniwaki, M
Ikeda, S
Tobinai, K
[J]. LEUKEMIA & LYMPHOMA, 2000, 38 (5-6) : 521 - 532
[26] CNOP (Mitoxantrone) chemotherapy is inferior to CHOP (Doxorubicin) in the treatment of patients with aggressive non-Hodgkin lymphoma (Review).
Bjorkholm, Magnus
Osby, Eva
Andersson, Tomas
Ahlbom, Anders
[J]. BLOOD, 2006, 108 (11) : 689A - 690A
[27] THP-COP regimen for the treatment of peripheral T-cell lymphoma and adult T-cell leukemia/lymphoma: a multicenter phase II study
Takamatsu, Yasushi
Suzumiya, Junji
Utsunomiya, Atae
Maeda, Koichi
Matsuoka, Hitoshi
Suzushima, Hitoshi
Tsukada, Junichi
Shibata, Keisuke
Tamura, Kazuo
[J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2010, 84 (05) : 391 - 397
[28] Phase I/II study of THP-COP therapy for old-age patients with advanced stage aggressive non-Hodgkin's lymphoma (NHL): Of lymphoma phase I study group (LPOSG) study on 30 patients older than 70 years.
Ogura, M
Kagami, Y
Hirose, T
Chou, T
Nagai, H
Kinoshita, T
Ohnishi, K
Ohmachi, K
Hotta, T
[J]. BLOOD, 2001, 98 (11) : 245B - 245B
[29] P-CHOP: Cisplatin (P) added to the standard CHOP regimen as first-line treatment for aggressive non-Hodgkin lymphoma - A single-institution phase II study
Cocconi, G
Franciosi, V
Dodero, A
Bologna, A
Vasini, G
De Lisi, V
Di Blasio, B
Ceci, G
Camisa, R
Cascinu, S
[J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2003, 26 (06): : 535 - 542
[30] A randomized comparison of the efficacy and toxicity of epirubicin and doxorubicin in the treatment of patients with non-Hodgkin's lymphoma
Nair, R
Ramakrishnan, G
Nair, NN
Saikia, TK
Parikh, PM
Joshi, SR
Soman, CS
Mukhadan, M
Dinshaw, KT
Advani, SH
[J]. CANCER, 1998, 82 (11) : 2282 - 2288

← 1 2 3 4 5 →